Eculizumab treatment during pregnancy does not affect the complement system activity of the newborn
Open Access
- 1 April 2015
- journal article
- research article
- Published by Elsevier in Immunobiology
- Vol. 220 (4) , 452-459
Abstract
No abstract availableKeywords
Funding Information
- The Research Council of Norway (230526/F20, 179573/V40)
- The Norwegian Council on Cardiovascular Disease
- the Northern Norway Regional Health Authority
- The Southern and Eastern Norway Regional Health Authority
- The Odd Fellow Foundation
- European Community's Seventh Framework Programme (602699)
- South-Eastern Norway Regional Health Authority (39375)
This publication has 52 references indexed in Scilit:
- Long‐term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuriaBritish Journal of Haematology, 2013
- Complement factor H genotypes impact risk of age-related macular degeneration by interaction with oxidized phospholipidsProceedings of the National Academy of Sciences, 2012
- IgG Placental Transfer in Healthy and Pathological PregnanciesJournal of Immunology Research, 2011
- Complement: a key system for immune surveillance and homeostasisNature Immunology, 2010
- Human genetic deficiencies reveal the roles of complement in the inflammatory network: Lessons from natureProceedings of the National Academy of Sciences, 2009
- The role of the anaphylatoxins in health and diseaseMolecular Immunology, 2009
- How I treat paroxysmal nocturnal hemoglobinuriaBlood, 2009
- Conditional deletion of the MHC class I-related receptor FcRn reveals the sites of IgG homeostasis in miceProceedings of the National Academy of Sciences, 2009
- Complement activation and inhibition: a delicate balanceTrends in Immunology, 2009
- Rituximab Administration in Third Trimester of Pregnancy Suppresses Neonatal B-Cell DevelopmentJournal of Immunology Research, 2008